Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Immunomic Therapeutics, Inc.

  • Bill Hearl, Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to generate broad immune responses. ITI’s UNITE platform has broad therapeutic applications in oncology, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics and ITI has built a large pipeline from UNITE with six oncology programs and two allergy programs. ITI's technology has been deployed in over 135 oncology patients and 210 allergy patients and in oncology, has demonstrated survival benefit and immune system activation in the clinic. Due to its expertise in the field, ITI entered into a significant allergy partnership with Astellas Pharma and has formed several academic collaborations with leading Immuno-oncology researchers.

  • Date:Tuesday, February 12
  • Time:2:00 PM - 2:15 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23285
  • Goal for Presentation:Visibility and Funding
  • Company Website:www.immunomix.com
  • Company HQ City:Rockville
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$25M
  • Year Founded:2006
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:ITI-1000
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):6
Speakers
Bill Hearl
Immunomic Therapeutics, Inc.
Back